H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
17%
Acceptance
Rate
call: +1.631.4701.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients na¨Ive to antiretrovirals

Xavier De La Tribonniere, Yves Mouton, Vincent Vidal, Edith Darcissac, Daouda Sissoko, Clothilde Fontier, Youcef Douadi, Joëlle Dewulf, Corinne Amiel, George Michael Bahr

Med Sci Monit 2003; 9(6): PI43-50

ID: 12743

Available online: 2003-06-25

Published: 2003-06-25


Background:Limitations in the use of antiretroviral therapy suggest the need for additional approaches to enhance immune restoration and the control of HIV-1 replication. Therefore, we evaluated the clinical tolerance and biological effects of immunotherapy with the synthetic immunomodulator Murabutide in 9 treatment-na¨lve HIV-1 patients presenting with CD4+ lymphocyte counts >500 cells/mm3 and plasma viral loads

Keywords: Acetylmuramyl-Alanyl-Isoglutamine - administration & dosage, Acetylmuramyl-Alanyl-Isoglutamine - analogs & derivatives, Acetylmuramyl-Alanyl-Isoglutamine - toxicity, Acquired Immunodeficiency Syndrome - drug therapy, Acquired Immunodeficiency Syndrome - immunology, Adjuvants, Immunologic - administration & dosage, Adjuvants, Immunologic - toxicity, Anti-HIV Agents - administration & dosage, Anti-HIV Agents - therapeutic use, Antigens, CD - blood, Antigens, CD - drug effects, CD4 Lymphocyte Count, Drug Administration Schedule, Humans, Injections, Subcutaneous, Lymphocyte Activation - drug effects



Back